GeoVax Secures Patent for Multi-Antigen COVID-19 Vaccine Technology
GeoVax Labs has obtained a key U.S. patent for its multi-antigen COVID-19 vaccine technology, strengthening its position in developing next-generation vaccines that could provide broader and more durable protection against evolving variants.
The U.S. Patent and Trademark Office has issued a Notice of Allowance for GeoVax Labs' patent application covering recombinant Modified Vaccinia Ankara viral vectors encoding multiple SARS-CoV-2 proteins, including Spike, Membrane, and Envelope antigens. This technology is designed to generate virus-like particles that induce both antibody and T-cell responses, providing durable and broad immune protection against current and emerging variants of SARS-CoV-2.
The allowed claims cover multi-antigen designs that mimic the natural virus structure and induce robust immune responses through VLP formation within host cells, enabling presentation of antigens in their natural conformation for optimal immune recognition. The patent protection extends to both ancestral strain sequences and variant-associated mutations such as K417N/T, E484K, and N501Y, addressing concerns about immune escape by new viral variants.
David Dodd, GeoVax President and CEO, stated that this allowance represents an important strengthening of the company's intellectual property estate protecting next-generation, multi-antigen COVID-19 vaccines. Unlike single-antigen vaccines, GeoVax's MVA-based multi-antigen constructs are designed to elicit durable, broad-spectrum protection even as the virus continues to evolve.
The newly allowed patent covers constructs central to GeoVax's CM01 and CM02 vaccine candidates, which express multiple SARS-CoV-2 proteins to generate virus-like particles in vaccinated individuals. These vaccine designs are intended to provide broad and durable protection by engaging both arms of the immune system and countering immune escape by new viral variants. Together with GEO-CM04S1, which is advancing through Phase 2 clinical trials in immunocompromised and healthy populations, CM01 and CM02 position GeoVax as a leader in next-generation COVID-19 vaccine innovation.
This patent allowance comes at a critical time as the COVID-19 pandemic continues with emerging variants challenging existing vaccine efficacy. The multi-antigen approach represents a significant advancement over single-antigen mRNA vaccines by potentially providing more comprehensive and longer-lasting protection. For more information about the company's technology and clinical programs, visit https://www.geovax.com.
The intellectual property protection strengthens GeoVax's competitive position in the vaccine market and could facilitate partnerships or licensing opportunities. The company's focus on multi-antigen technology addresses a growing need for vaccines that can keep pace with viral evolution and provide protection for vulnerable populations, including immunocompromised patients for whom current authorized COVID-19 vaccines may be insufficient.